Mechanisms by which the cystic fibrosis transmembrane conductance regulator may influence SARS-CoV-2 infection and COVID-19 disease severity.
Tedbury PR, Manfredi C, Degenhardt F, Conway J, Horwath MC, McCracken C, Sorscher AJ, Moreau S, Wright C, Edwards C, Brewer J, Guarner J, de Wit E, Williamson BN, Suthar MS, Ong YT, Roback JD, Alter DN, Holter JC, Karlsen TH, Sacchi N, Romero-Gómez M, Invernizzi P, Fernández J, Buti M, Albillos A, Julià A, Valenti L, Asselta R, Banales JM, Bujanda L, de Cid R, Franke A; Severe COVID-19 GWAS group; Sarafianos SG, Hong JS, Sorscher EJ, Ehrhardt A.
Tedbury PR, et al. Among authors: de cid r, de wit e.
FASEB J. 2023 Nov;37(11):e23220. doi: 10.1096/fj.202300077R.
FASEB J. 2023.
PMID: 37801035
Free PMC article.